Early-Stage Cancer Biomarker Testing and Treatment Landscape Assessment

Project Overview

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

DeciBio Approach

Secondary Research

Reviewed biomarker epidemiology and testing as well as treatment guidelines to identify the specific patient populations for which testing and/or treatment pathways may be most affected by the approval of the new therapy

Primary Research

Conducted 65 in-depth interviews with oncologists, pulmonologists, surgeons, and pathologists to gain deep understanding of the testing and treatment workflow
Interviews spanned the U.S. and EU and varying institution types, including academic medical centers, community hospitals, network hospitals, and private practices

At a glance

Interviews

Stakeholder Types

Institution Types

Outcomes

DeciBio delivered an in-depth semi-quantitative biomarker testing and treatment landscape analysis (e.g., landscape today, key trends, and expected future growth).

Quantitative and qualitative assessment included:

Current testing and treatment practices by geography and biomarker status
Biomarker testing technology utilization by institution type and geography
Clinician behaviors by setting and geography, including rationale
Key testing considerations and drivers by geography, stakeholder type; pain points by biomarker
Expected changes in testing behaviors in various clinical scenarios
Stakeholder archetypes by setting, including detailed summaries of stakeholder perspectives on trends and growth

DeciBio's analysis revealed that the risk of patient attrition from the client's treatment pathway was lower than expected, and DeciBio developed specific tactics the client could implement to mitigate the attrition of those patients who were at risk.

Timeline

11 weeks

Geographic Scope

U.S. and EU

Industry

Pharma & Biotech

capabilities

Competitive Analysis

Biomarker and Diagnostic Strategy

Voice-Of-Customer Research

Cell and Gene Therapy Services Landscape Assessment

Cell and Gene Therapy Service Market Opportunity Assessment

Synthetic Oligonucleotides Market Sizing